Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Becton, Dickinson and Company

Market Cap 38.77B 34.06B 31.38B 29.38B 55.05B 3,673B 55.97B 377B 146B 1,802B 146B 142B 6,263B P/E 2026 *
35.1x
P/E 2027 * 27.1x
Enterprise Value 54.73B 48.08B 44.3B 41.47B 77.7B 5,184B 79.01B 532B 206B 2,544B 205B 201B 8,841B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.68x
Free-Float
74.04%
Yield 2026 *
2.74%
Yield 2027 * 2.78%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 38.77B
+3.22%-0.25%-32.17%-16.34% 153B
+1.37%-1.39%-6.71%-8.33% 101B
-1.82%-0.54%+56.86%+55.61% 55.9B
+4.25%+0.26%-3.74%+50.36% 52.78B
+1.63%-5.10% - - 29.35B
+0.59%-5.08%-13.02%-45.21% 26.65B
+1.39%+1.56%+54.46%-8.80% 23.29B
-2.25%-1.92%-16.37%-5.76% 20.51B
+0.83%-2.33%-14.87%-4.33% 19.53B
Average +0.93%-2.41%+3.05%+2.15% 53.61B
Weighted average by Cap. +1.58%-1.78%-5.13%+1.78%

Financials

2026 *2027 *
Net sales 19.21B 16.87B 15.55B 14.55B 27.27B 1,819B 27.73B 187B 72.26B 893B 72.1B 70.54B 3,102B 19.71B 17.32B 15.96B 14.94B 27.98B 1,867B 28.46B 192B 74.16B 916B 73.99B 72.4B 3,184B
Net income 1.12B 988M 910M 852M 1.6B 107B 1.62B 10.93B 4.23B 52.27B 4.22B 4.13B 182B 1.45B 1.27B 1.17B 1.1B 2.06B 137B 2.09B 14.09B 5.45B 67.36B 5.44B 5.32B 234B
Net Debt 15.95B 14.02B 12.92B 12.09B 22.65B 1,511B 23.03B 155B 60.03B 742B 59.89B 58.61B 2,577B 14.07B 12.36B 11.39B 10.66B 19.98B 1,333B 20.32B 137B 52.95B 654B 52.83B 51.69B 2,273B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
140.71USD
Average target price
177.75USD
Spread / Average Target
+26.32%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!